| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 216.17 | 78.8% |
| Total Income | 216.17 | 78.8% |
| Expenditure | 210.89 | 17.9% |
| PBT | -0.64 | 99.4% |
| Net Profit | -0.51 | 99.5% |
| OPM | 2.44% | 50.37pp |
| NPM | -0.24% | 84.60pp |
| EPS | 0.00 | 100.0% |
Caris Life Sciences Reports Q1 2026 Revenue of $216.2 Million, Up 79%
08 May 2026 · 8 May, 1:54 am
Summary
Caris Life Sciences reported a strong first quarter in 2026, with total revenue reaching $216.2 million, a 79% increase compared to the same period last year. The growth was primarily driven by an 85% increase in molecular profiling services revenue. Gross margin improved significantly to 65%. The company reaffirms its full year 2026 revenue guidance to be in the range of $1.0 billion to $1.02 billion.
Key Highlights
- 1
Caris Life Sciences reported total revenue of $216.2 million for Q1 2026, representing a 79% increase over the prior year period.
- 2
The company completed approximately 52,800 clinical therapy selection cases, a 15% increase year-over-year.
- 3
Gross margin improved by approximately 1,800 bps to 65% compared to the corresponding prior year period.
- 4
Caris Life Sciences reported a net loss of $0.5 million for the quarter.
- 5
Adjusted EBITDA was reported as a positive $26.2 million.
- 6
Net cash provided by operating activities was $32.9 million, with a free cash flow of $22.5 million, inclusive of annual bonus payments of $30.5 million.
- 7
The company reaffirms its full year 2026 revenue guidance to be in the range of $1.0 billion to $1.02 billion, representing growth of 23% to 26% compared to full year 2025.
Management Comments
David Dean Halbert
We delivered another strong quarter with record performance for February and March following our January sales re-alignment. This performance underscores the continued demand for our platform and the strength of our comprehensive, patient-first approach. We are also encouraged by the Achieve 1 data, including the blinded readout, which demonstrates the superior performance of our whole genome technology over inferior techniques such as methylation. We remain focused on strengthening Caris Detect through the incorporation of additional pillars in advance of our upcoming launch.
Informational and educational content only. Not investment advice.